Navigation Links
NIH Grants Exclusive License to Theranostics Health
Date:4/21/2008

ROCKVILLE, Md., April 21 /PRNewswire/ -- Theranostics Health announced that it has received an exclusive license from the National Institutes of Health (NIH) to commercialize microdissection including Laser Capture Microdissection (LCM) combined with protein analysis for cancer diagnostics and companion diagnostics. Under the terms of the agreement, Theranostics Health will pay NIH the customary license issue royalties, minimum annual royalties, benchmark and earned royalties upon successful commercialization of the technology.

Theranostics was founded on the vision of shaping a new paradigm in disease management with two primary and complementary goals; arming physicians with accurate diagnostic tests so that they can tailor treatment based on the individual patient's aberrant signaling profile and enabling drug developers to better stratify clinical cohorts in clinical trials to efficiently develop safer and more effective drugs.

Dr. Lance Liotta, co-inventor of the technology, co-founder and Chief Medical Officer of the Company said, "Existing methods of genomic and proteomic tissue profiling analysis that do not rely on LCM have been shown to produce inaccurate and possibly misleading results, arising from heterogeneity of tissues and variation in cellular compositions between samples and within different regions of a tissue sample. This licensed technology allows us to precisely collect and analyze the specific cells of interest from patient samples." "But this is only the first step," according to Dr. Emanuel F. Petricoin, co-inventor of the technology, co-founder and Chief Scientific Officer of the Company, "our unique signaling pathway profiling platform allows the activity of theranostic biomarkers of interest to be quantitatively measured from microdissected patient samples. With this technology and our experience and expertise in disease signaling pathways, we are discovering new ways of more effectively treating patients with existing drugs and treating patients who are resistant to their current therapies."

"This exclusive license allows Theranostics Health to commercially develop companion diagnostics for treatment decision and monitoring, providing direct benefit to patients as well as building significant value for our shareholders," added the Company's President and CEO, Dr. Danong Chen.

About Theranostics Health

Theranostics Health is a privately held company founded in 2006. Its core technology is the breakthrough Reverse Phase Protein Microarray (RPMA) combined with Laser Capture Microdissection (LCM). The technology measures the activity of a large number of biomarkers, enabling pharmaceutical companies to accurately profile their drug candidates to facilitate efficient and effective drug development. More importantly, it enables physicians to tailor optimized therapies to their patients based on the biomarker profile of each individual patient, providing safer and more effective therapies. The technology, invented by the company's co-founders Drs. Emanuel Petricoin and Lance Liotta, was first published by them in 2001, has been featured in over 50 peer-reviewed publications and 20 scientific presentations within the past 2 years, and was successfully used in NCI-sponsored clinical trials. Currently, Theranostics Health is working with 5 of the top 10 global pharmaceutical companies in their drug R&D efforts. The company closed its seed financing of $5 million in 2007 and generated revenue in its first year of operations. For more information please email info@theranosticshealth.com or visit http://www.theranosticshealth.com.


'/>"/>
SOURCE Theranostics Health
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Life Sciences Fund grants awards to launch health research
2. American Cancer Society awards research grants to 133 investigators at 84 institutions nationwide
3. Highmark Healthy High 5 School Challenge Program Awards $605,000 in Grants to 75 Pennsylvania Schools
4. Arthritis Foundation Grants Ease-Of-Use Commendation to Duracell EasyTab Hearing Aid Battery
5. ILC-USA and MetLife Foundation Launch Second Year of Community College Caregiver Training Grants
6. American Psychiatric Foundation Announces Recipients of 2008 Helping Hands Grants
7. Governor Rendell Proposes County Grants to Combat West Nile Virus, Protect Public Health
8. The United States Patent and Trademark Office Grants TransUnion Patent for Healthcare Financing Method
9. Nasdaq Hearings Panel Grants TeamStaffs Request for Continued Listing Subject to a Reverse Stock Split
10. Lilly Grants $4.4 Million to the WHO for MDR-TB Program Expansion
11. Burroughs Wellcome Fund grants $9.75 million towards translational researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Aliso Viejo, California (PRWEB) , ... June 27, 2016 , ... ... that are fully customizable inside of Final Cut Pro X," said Christina Austin - ... with another unique style. Final Cut Pro X users can now reveal ...
(Date:6/27/2016)... , ... June 27, 2016 , ... TopConsumerReviews.com recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... Cary, North Carolina (PRWEB) , ... June 26, 2016 , ... ... the release of a new product that was developed to enhance the health of ... harvested for centuries. , The two main herbs in the PawPaws Cat Kidney ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research and ... Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data derived ... Assessment of major trends with potential impact on the market ... of market segmentation which comprises of sub markets, regional and ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology: